Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03898336
Other study ID # VANTASTIC STUDY
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 18, 2019
Est. completion date September 30, 2022

Study information

Verified date April 2021
Source Radboud University
Contact Ruth Berg
Phone +49 621 / 1703
Email ruth.berg@zi-mannheim.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Impulsivity, irritability and compulsivity are cross-disorder symptom domains, which affect a significant proportion of adolescents. Predominately as part of attention deficit hyperactivity disorder (ADHD) but also as symptom domains without a diagnosis of ADHD, impulsivity and irritability cause serious burden. Furthermore, treatment options and their effects are limited. Previous studies with different study designs assessing micronutrients for the treatment of impulsivity / ADHD in children and adults have reported positive benefits as well as a very good tolerability. However, more research is required; in particular controlled studies with adolescents, cross-disorder approaches and studies investigating long-term effects are missing. The focus of this study is to investigate the effect of micronutrients on impulsivity, irritability and compulsivity in children and adolescents between 11 and 18 years of age with a high level of impulsivity and irritability with or without a diagnosis of attention deficit hyperactivity disorder (ADHD). The investigators intend to include 210 children and adolescents (n=110 in Germany) with a high level of impulsivity and irritability. The study is divided in two phases. An initial 10-week double blind, placebo-controlled treatment phase with broad-spectrum micronutrients is followed by a 10-week open-label treatment phase. The study assessments will be performed during five study visits and a follow-up visit.


Recruitment information / eligibility

Status Recruiting
Enrollment 210
Est. completion date September 30, 2022
Est. primary completion date September 30, 2022
Accepts healthy volunteers No
Gender All
Age group 11 Years to 18 Years
Eligibility Inclusion Criteria: - Male or female, aged 11;0 - 17; 6 years at initial inclusion - Subjects with a high level of impulsivity/ irritability based on a CGI-S-score = 4 and a parent-rated Affective Reactivity Index (ARI) score = 5 indicating a high level of multi-dimensional irritability - Subjects with or without a research diagnosis of attention deficit hyperactivity disorder (ADHD). ADHD has to be confirmed by structured diagnostic interview (ADHD section of Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS)) - Deemed reliable and compliant with the protocol (including the ingestion of as many capsules as prescribed by the investigator) - Ability to comprehend and speak the native language of the country in which the assessments take place - Signed informed consent by parents or legal representative - Signed informed assent by child or adolescent (indicating that the subject is aware of the investigational nature and the core aspects of the study and the study is run in accordance with the ICH GCP guideline E6 (R2) (2016)) Exclusion Criteria: - Subject is being treated with a medication that might, in the opinion of the investigator, pose a safety risk for the subject when participating in this study - Intellectual disability (based on available IQ or the clinical opinion of the investigator, taking into account relevant psychosocial information, e.g. educational level) - Any known abnormality of mineral metabolism (e.g., Wilson's disease, haemochromatosis) - History of or present clinically relevant somatic or psychiatric acute or chronic disorder that, in the opinion of the investigator, might confound the results of tolerability/safety assessment, or prohibit the patients from completing the study, or would not be in the best interest of the patient. - Subject has taken any kind of food supplement containing vitamins, minerals and/or trace elements within 30 days prior to entering the study - Subject has unstable treatment conditions (current changes in medication and/or psychotherapy) that might in the opinion of the investigator confound the results of the study with respect to impulsivity/irritability. - Subject has a documented allergy, hypersensitivity, or intolerance to any of the ingredients of the investigational product - Subject has taken another investigational product or taken part in a clinical study within 30 days prior to entering the study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
broad-spectrum micronutrient
daily intake of capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)
placebo
daily intake of capsules

Locations

Country Name City State
Germany Central Institute of Mental Health Mannheim

Sponsors (3)

Lead Sponsor Collaborator
Radboud University Central Institute of Mental Health, Mannheim, University Medical Center Groningen

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary response rate at end of placebo-controlled phase defined as CGI-I score with focus on impulsivity of 1 or 2 [=very much improved or much improved] plus reduction in Affective Reactivity Index (ARI) total score of at least 30% compared to baseline The primary objective is to investigate the double-blind placebo controlled (10 weeks) effects of broad-spectrum micronutrients in highly impulsive children and adolescents (10-18 years; N=180 in total) with a high level of impulsivity with or without diagnosis of attention deficit hyperactivity disorder (ADHD). The primary outcome measure is the response rate at the end of the placebo-controlled phase. Response is defined as a Clinical Global Impression - Improvement score (CGI-I, Guy 1976; NIMH 1985) with a focus on impulsivity of 1 or 2 [=very much improved or much improved] plus a reduction in the Affective Reactivity Index (ARI, parent-rated, Stringaris et al. 2012) total score of at least 30% compared to baseline. 10 weeks (end of placebo-controlled phase)
Secondary Change in Clinician rating of compulsivity ChildrenĀ“s Yale-Brown Obsessive-Compulsive Scale (CY-BOCS, Scahill et al., 1997) every 10 weeks over the whole study period of 20 weeks (10 weeks placebo-controlled phase followed by 10 weeks open label)
Secondary Change in the rating of irritability Perceived Stress Scale (PSS-10, Taylor 2015) every 10 weeks over the whole study period of 20 weeks (10 weeks placebo-controlled phase followed by 10 weeks open label)
Secondary Change in sleep problems Sleep problems (5-item questionnaire, self-rating of sleep problems) every 10 weeks over the whole study period of 20 weeks (10 weeks placebo-controlled phase followed by 10 weeks open label)
Secondary change in motor activity (optional) mHealth (movisens DataAnalyzer software) at baseline and after 10 weeks of study participation
Secondary Change in ADHD symptom severity total score Swanson, Nolan and Pelham Rating Scale (SNAP, Swanson et al. 2001) every 10 weeks over the whole study period of 20 weeks (10 weeks placebo-controlled phase followed by 10 weeks open label)
Secondary change in rating of aggression Retrospective Modified Overt Aggression Scale (R-MOAS, Blader et al. 2010) every 5 weeks over the whole study period of 20 weeks (10 weeks placebo-controlled phase followed by 10 weeks open label)
Secondary Rates of adverse events of the treatment groups in comparison to placebo group Compare rates of adverse events of the treatment groups to placebo group to assess safety and tolerability every 5 weeks over the whole study period of 20 weeks (10 weeks placebo-controlled phase followed by 10 weeks open label)
Secondary change in treatment adherence assessed by Attitudes Towards Treatment questionnaire; total score 0-108; better Outcome: lower score every 10 weeks over the whole study period of 20 weeks (10 weeks placebo-controlled phase followed by 10 weeks open label)
See also
  Status Clinical Trial Phase
Completed NCT03484377 - Cortical Dynamics of Inhibitory Control: A Concurrent tDCS-MEG Study N/A
Terminated NCT03527550 - Cognitive Control Training for Urgency in a Naturalistic Clinical Setting N/A
Recruiting NCT05894980 - How to Reduce Suicidal Thoughts and Impulsivity in Depression N/A
Recruiting NCT03218670 - Your Health in On Click N/A
Not yet recruiting NCT04811807 - Clinical Response of Impulsivity After Brain Stimulation in Parkinson's Disease
Completed NCT02740582 - Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users Phase 2
Not yet recruiting NCT02595164 - Common Decision Making Deficits in Suicidal Behaviors and Eating Disorders N/A
Recruiting NCT04960969 - The Effects of Time-Restricted Eating Model N/A
Not yet recruiting NCT06226467 - Neurobehavioral Affective Control Training N/A
Not yet recruiting NCT03498937 - Effects of tDCS on Impulsiveness Among People Suffering From Borderline Personality Disorder N/A
Completed NCT03200873 - Effects of rTMS on Impulsivity and Empathy N/A
Terminated NCT03838484 - Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia N/A
Completed NCT04290533 - HD-tDCS Over the dACC in High Trait Impulsivity N/A
Completed NCT05031559 - Episodic Future Thinking and Compassion N/A
Completed NCT01158950 - A Study of Neural Circuit Responses to Catechol-O-methyl Transferase (COMT) Inhibitors N/A
Recruiting NCT05875181 - Examining the Impact of Transcranial Focused Ultrasound (tFUS) on Reward Neural Circuitry N/A
Not yet recruiting NCT03190681 - Motivation and Methylphenidate Early Phase 1
Completed NCT01805401 - tDCS Applied to the OFC: Effects on Decision-Making and Impulse Control N/A
Completed NCT03006653 - Understanding Daily Fluctuations in Self-Regulation N/A
Active, not recruiting NCT04785677 - Researching Resiliency in Stressful Experiences (RISE) Program for Men Leaving Incarceration N/A